Mr. Wei Xu is a Partner at Decheng Capital and has been with the firm since 2017. He is currently serving on the boards of Accuragen, AnHeart Therapeutics (acquired by Nuvation Bio), Centricity Vision, Ketai Medical, MDCO and USCI Medical Laboratory.
Prior to joining Decheng, Mr. Xu was Managing Director of Denlux Capital and served on the boards of Cirina (acquired by GRAIL), BEST (NYSE: BSTI), and SINOMED (688108.CH).
Mr. Xu received Master degree in Economics from University of Oslo, and a BS degree in College of Biomedical Engineering & Instrument Science from Zhejiang University.